Natera Reports 38.8% Revenue Growth to $696.6 Million in Q1 2026

Natera, Inc. reported significant financial results for the first quarter of 2026, with total revenues reaching $696.6 million, a 38.8% increase from $501.8 million in the same period of 2025. The growth was primarily driven by product revenues, which accounted for $693.9 million, up from $500.0 million year-over-year. Despite this revenue growth, the company recorded a net loss of $85.1 million, compared to a loss of $66.9 million in the prior year, reflecting an increase in operational costs and expenses.

The company's cost of product revenues also rose, increasing by 32.8% to $245.2 million, attributed to higher inventory consumption, labor costs, and third-party fees. Research and development expenses surged by 63.2% to $210.7 million, driven by increased headcount and clinical trial-related costs. Selling, general, and administrative expenses rose by 22.9% to $327.9 million, reflecting higher personnel costs and marketing expenses. The overall total cost and expenses for the quarter were $790.2 million, up from $581.0 million in the previous year.

Natera's operational metrics showed a positive trend, with approximately 1,013,600 tests processed during the quarter, compared to 855,100 tests in the same period last year. The company continues to focus on expanding its product offerings, particularly in oncology and women's health, with key products including Signatera, Panorama, and Horizon. The company also noted that 96% of its revenues were generated from its U.S. direct sales force, consistent with the previous year.

Strategically, Natera completed the acquisition of Foresight Diagnostics in December 2025, which is expected to enhance its capabilities in molecular residual disease detection. The acquisition involved a total purchase consideration of $424.5 million, including contingent consideration based on performance milestones. As of March 31, 2026, Natera had $1.1 billion in cash and cash equivalents, with an outstanding balance of $80.3 million on its credit line, indicating a solid liquidity position to support ongoing operations and growth initiatives.

Looking ahead, Natera anticipates continued revenue growth driven by increased demand for its tests and expansion into new markets. However, the company acknowledges the need for additional financing to support its operations and product development, as it expects to incur net losses in the near future. The management remains focused on enhancing reimbursement rates and expanding its market presence to achieve long-term profitability.